[Stem Cells/BBB] Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier

Vatine et al. show that human iPSC-based modeling can pinpoint the origin of a neuronal disorder in the brain as a defect in transport of thyroid hormone across the blood-brain barrier, rather than in the neurons themselves.

Source: Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier

[Stem Cells/BBB] Huntington’s Disease iPSC-Derived Brain Microvascular Endothelial Cells Reveal WNT-Mediated Angiogenic and Blood-Brain Barrier Deficits

Lim et al. show that HD iPSCs-derived brain microvascular endothelial cells have impaired angiogenic and barrier properties. Transcriptomic analysis provides mechanistic insights into pathways that underlie dysfunction, and WNT inhibition prevents angiogenic deficits. This system also suggests strategies to reduce disease burden and assess BBB penetration of drugs for HD.

Source: Huntington’s Disease iPSC-Derived Brain Microvascular Endothelial Cells Reveal WNT-Mediated Angiogenic and Blood-Brain Barrier Deficits

The Supreme Court rules out iPSCs cell patent

If you are in the stem cell field, you know that one of the problem actually mining the field like a minefield is the intellectual properties and patents. Especially here in the US, in which both human embryonic (hESCs) and induced pluripotent stem cells (iPSCs) are subject to patents and IP through the Wisconsin Alumni Research Foundation (WARF).

That have created some stirs with a series of court decisions to define if WARF have the rights to patent these stem cells and hold exclusive aspect of it. This of course ended up at the Supreme Court to get the final word on it.

Well it seems the Supreme Court get its final word to end up its imbroglio, according to U-T San Diego and reported by the Genetics Policy Institute:http://www.utsandiego.com/news/2015/feb/24/supreme-court-rejects-warf-patent-case/

And the final word was a “Yeah!” for the embryonic stem cells (in other words WARF keep their exclusive patents and licensing on them) but a “Nay!” for the iPSCs, in other means anyone could derive the iPSCs without having to request a license to do so from WARF.

Now let’s see how things deconvolute and how the fallout of this news will shake the stem cell field but I think an old post from Pr. Paul Knoepfler worth to be updated in the light of the newest development, here is the original link to the article: Putting the IP in iPS cells: patent war looming? | Knoepfler Lab Stem Cell Blog.

First iPSC human clinical in Japan started

Today is a big milestone in stem cell research. We are assisting the first clinical trial involving iPSC, in other patient-derived cells designed to treat a disease. Imagine that, I take a small piece of your skin cells, I reprogram them to become pluripotent (or induced pluripotent stem cells, iPSCs) and then ask them to become retinal cells, because you suffer from an eye disease.
This was science fiction 10 years ago and today we are up to the first trial in patients! This is why science is so great. Keep it tuned!